Financial Performance - The company's operating revenue for 2024 reached ¥5,233,420,808.02, representing a 34.07% increase compared to ¥3,903,503,781.52 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥26,574,897.24, a decrease of 22.52% from ¥34,299,844.15 in 2023[17]. - The net profit after deducting non-recurring gains and losses was ¥25,606,109.23, down 25.40% from ¥34,322,553.37 in 2023[17]. - The total assets at the end of 2024 amounted to ¥6,178,190,385.57, an increase of 17.06% from ¥5,277,655,319.75 at the end of 2023[17]. - The basic earnings per share for 2024 was ¥0.13, a decline of 23.53% compared to ¥0.17 in 2023[17]. - The weighted average return on equity for 2024 was 1.52%, down from 1.98% in 2023[17]. - The net cash flow from operating activities for 2024 was ¥24,041,119.19, a decrease of 11.39% from ¥27,130,076.95 in 2023[17]. - The company reported a net profit of ¥4,616,350.00 in Q3 2024, significantly lower than the profit of ¥12,397,081.78 in Q2 2024[19]. - The company achieved a total revenue of ¥5,233,420,808.02 in 2024, representing a year-on-year growth of 34.07%[48]. - Net profit for 2024 reached ¥51,330,200, marking a 35.05% increase compared to the previous year[48]. Dividend Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of 0.818 RMB per 10 shares, based on a total of 205,403,200 shares[5]. - The company plans to distribute a cash dividend of RMB 0.818 per 10 shares, totaling RMB 16,801,981.76 for the year 2024[158]. - The total distributable profit for the company as of December 31, 2024, is RMB 561,184,256.91, with the mother company having a distributable profit of RMB 56,072,544.43[157]. - The company will not issue new shares or convert capital reserves into share capital in the 2024 profit distribution plan[158]. - The company has a clear and transparent cash dividend policy, complying with relevant regulations and ensuring shareholder rights are protected[153]. Market Expansion and Strategy - The company plans to expand its market presence and enhance its product offerings through new technologies and research initiatives[11]. - The management discusses potential strategies for mergers and acquisitions to strengthen market position[11]. - The company is focusing on digital transformation and the integration of online and offline services to enhance its healthcare ecosystem[33]. - The company is actively expanding into the upstream pharmaceutical industry and enhancing its retail pharmacy resources[33]. - The company aims to enhance its R&D capabilities through increased investment and collaboration between its pharmaceutical distribution and industrial businesses[41]. - The company is focusing on developing an "Internet +" prescription drug retail model, expanding sales channels through collaborations with various apps and third-party e-commerce platforms, and building a shared platform for prescription flow between hospitals and pharmacies[96]. - The company aims to enhance its brand influence and market competitiveness through a comprehensive integration of its pharmaceutical distribution and manufacturing operations[48]. - The company is addressing the risk of regional business concentration by establishing subsidiaries in regions like Ningxia and Hainan, employing a "new build + acquisition + franchise" strategy for national expansion[99]. Research and Development - R&D expenses rose by 126.64% to ¥16,257,767.71, mainly driven by increased drug development costs in the industrial sector[56]. - The number of R&D personnel increased by 89.47% from 19 to 36, enhancing the company's R&D capacity[59]. - R&D investment for 2024 is ¥16,257,767.71, which is 0.31% of operating revenue, up from 0.18% in 2023[59]. - The company has five new R&D projects, including studies on Norfloxacin capsules and raw materials, aimed at expanding its product portfolio[59]. - The company is increasing R&D investment in traditional Chinese medicine and innovative drugs, aiming to enhance product quality and market competitiveness through technological upgrades[97]. Corporate Governance - The company has an independent financial accounting system and does not share bank accounts with the controlling shareholder, maintaining financial independence[123]. - The board consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[109]. - The company has implemented a performance evaluation and incentive mechanism for directors and senior management, promoting transparency and fairness[111]. - The company has established a robust internal management and control system, enhancing governance and operational efficiency[120]. - The company has actively improved its information disclosure practices, ensuring equal access to information for all shareholders[112]. Environmental Responsibility - Dajia Weikang adheres to multiple environmental standards, including air and water pollutant discharge standards, such as GB13271-2014 and GB21906-2008[173]. - The company holds a pollution discharge permit valid from February 13, 2023, to February 13, 2028[174]. - The company incurs annual costs of CNY 174,000 for wastewater treatment and CNY 17,000 for hazardous waste disposal[187]. - The company has implemented measures to monitor wastewater and air emissions regularly, ensuring compliance with environmental standards[180][182]. - Dajia Weikang has no recorded administrative penalties related to environmental issues during the reporting period[188]. Employee Management - The total number of employees at the end of the reporting period is 4,887, with 3,080 from major subsidiaries[146]. - The salary policy is based on a combination of ability and contribution, with total salary determined by annual budget and market conditions[148]. - Employee performance pay is directly linked to individual performance output and overall unit performance[148]. - The company provides statutory benefits including pension, medical, unemployment, work injury, maternity insurance, and housing fund[148]. - The company has established a wide salary system based on job levels to enhance employee motivation and efficiency[148]. Financial Management - The company has pledged assets totaling ¥425,941,689.19, including cash and fixed assets, for various loans and guarantees[70]. - The company reported a significant decrease in investment income, with a loss of ¥377,184.75, accounting for -0.50% of total profit[63]. - The company has utilized ¥54,367.87 million of the raised funds, representing 95.47% of the total raised amount[80]. - The company plans to use 1,700 million yuan of the raised funds to permanently supplement working capital[84]. - The company will focus on implementing investment projects from the raised funds to quickly achieve expected benefits, aligning with industry development trends and overall strategic direction[199].
达嘉维康(301126) - 2024 Q4 - 年度财报